Spyre Therapeutics, Inc. SYRE Investment Purchases
Investment Purchases at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s investment purchases.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s investment purchases?
- Spyre Therapeutics, Inc. (SYRE) reported investment purchases of $81.17M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s investment purchases changed year-over-year?
- Spyre Therapeutics, Inc.'s investment purchases increased by 13.6% year-over-year, from $71.44M to $81.17M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s investment purchases?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s investment purchases has grown at a 40.7% compound annual growth rate (CAGR), from $133.08M to $522.21M.
- What does investment purchases mean?
- Cash spent purchasing investment securities across all categories.